Table S1 - Catechol-O-Methyltransferase Val158Met Polymorphism Is Associated with Somatosensory Amplification and Nocebo Responses

CsA serum levels and IL-2 protein concentrations during the Medication and “Placebo” condition of the COMT genotype groups. CsA treatment during Medication significantly increased CsA serum levels and significantly suppressed IL-2 protein concentrations after anti-CD3 stimulation in all COMT genotype groups. During the “Placebo” condition, treatment with subtherapeutical doses of CsA slightly increased CsA levels in Val158/Val158, Val158/Met158 as well as Met158/Met158 allel carriers, however did not significantly affect IL-2 concentrations in these groups. (ANOVA, *p (DOCX)